Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Intangibles: 2010-2025

Historic Intangibles for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to $4.2 million.

  • Lifecore Biomedical's Intangibles changed negligibly% to $4.2 million in Q2 2025 from the same period last year, while for May 2025 it was $4.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $4.2 million for FY2025, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Intangibles is $4.2 million, which was down 0.00% from $4.2 million recorded in Q1 2025.
  • Lifecore Biomedical's Intangibles' 5-year high stood at $4.2 million during Q1 2021, with a 5-year trough of $4.2 million in Q1 2021.
  • Moreover, its 3-year median value for Intangibles was $4.2 million (2025), whereas its average is $4.2 million.
  • Data for Lifecore Biomedical's Intangibles shows a maximum YoY slumped of 85.97% (in 2021) over the last 5 years.
  • Over the past 5 years, Lifecore Biomedical's Intangibles (Quarterly) stood at $4.2 million in 2021, then remained steady at $4.2 million in 2022, then remained steady at $4.2 million in 2023, then remained steady at $4.2 million in 2024, then remained steady at $4.2 million in 2025.
  • Its Intangibles was $4.2 million in Q2 2025, compared to $4.2 million in Q1 2025 and $4.2 million in Q4 2024.